Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 0.67 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.56 |
| ▸ | PLAU | P00749 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | TPMT | P51580 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34463427 | 1.00 | KDM4E (1.00) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3541422 | 0.98 | KDM4E (0.96) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL5875335 | 0.98 | KDM4E (0.96) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL1145072 | 0.96 | KDM4E (0.93) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL8461552 | 0.94 | KDM4E (0.89) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| Cyanide SCHEMBL11199466 | 0.94 | KDM4E (0.89) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL7560634 | 0.89 | KDM4E (0.80) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| Methoxymethane SCHEMBL6861468 | 0.87 | KDM4E (0.77) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL8459975 | 0.87 | KDM4E (0.77) | KDM4ECA1CA2CYP1A2ALDH1A1 | |
| SCHEMBL9702751 | 0.87 | KDM4E (0.77) | KDM4ECA1CA2CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119841727-A | Method for directly preparing carboxylic ester compound from aromatic aldehyde, ketone and carboxylic acid | 湖南第一师范学院 | 2025-04-18 | — | — | CN | claimed |
| CN-119799320-A | Organic narrow-band afterglow material based on halation benzene derivative and preparation and application methods thereof | 中国科学院上海有机化学研究所 | 2025-04-11 | — | — | CN | claimed |
| CN-119638770-A | Clobetasol propionate derivative and preparation method thereof | 复旦大学 | 2025-03-18 | — | — | CN | claimed |
| CN-119528737-A | Small molecular compound DHN and preparation method and application thereof | 厦门大学 | 2025-02-28 | — | — | CN | claimed |
| CN-118184679-A | Photothermal agent and preparation method thereof, photothermal nanoparticle and preparation method thereof, insulating material and self-repairing method of insulating material | 中国石油天然气股份有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-116836081-A | Ether epoxy toughening agent and preparation method and application thereof | 中国林业科学研究院林产化学工业研究所 | 2023-10-03 | — | — | CN | claimed |
| US-10191398-B2 | Electrophotographic photoconductor, image forming apparatus, and process cartridge | RICOH COMPANY, LTD. (JP) | 2019-01-29 | — | — | US | claimed |
| EP-2463345-B1 | Ink composition, recording method using the same and recorded material | SEIKO EPSON CORP (JP) | 2017-01-18 | — | — | EP | claimed |
| EP-1749864-B1 | INK COMPOSITION, AND INK JET RECORDING METHOD AND RECORDED MATTER USING THE SAME | SEIKO EPSON CORP (JP) | 2015-07-22 | — | — | EP | claimed |
| EP-1676891-B1 | INK COMPOSITION AND INKJET RECORDING METHOD AND RECORDED MATTER USING THE SAME | SEIKO EPSON CORP (JP) | 2015-05-27 | — | — | EP | claimed |
| US-6984032-B2 | Ink composition, ink set, recording process and recorded matter | SEIKO EPSON CORPORATION (JP) | 2006-01-10 | — | — | US | claimed |
| US-20050115459-A1 | Magenta ink composition | SEIKO EPSON CORPORATION | 2005-06-02 | — | — | US | claimed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | claimed |
| US-20040174420-A1 | Ink composition, ink set, recording process and recorded matter | SEIKO EPSON CORPORATION | 2004-09-09 | — | — | US | claimed |
| US-20040003755-A1 | Ink composition, inkjet recording method using the same and recorded matter | SEIKO EPSON CORPORATION | 2004-01-08 | — | — | US | claimed |
| EP-1357158-A1 | Ink composition, inkjet recording method using the same and recorded matter | SEIKO EPSON CORPORATION (JP) | 2003-10-29 | — | — | EP | claimed |
| WO-2002000651-A2 | FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-03 | — | — | WO | claimed |
| US-6180830-B1 | REDUCING COMPLEX OF RUTHENIUM HAVING ELECTROVALENCY OF-4 AND COORDINATION NUMBER OF 6, WHEREIN AT LEAST ONE LIGAND IS TIN HALIDE, OTHER LIGANDS OPTIONALLY BEING HALOGEN ATOMS | RHODIA CHIMIE (FR) | 2001-01-30 | — | — | US | claimed |
| EP-0700890-B1 | Process for the preparation of aldehydes by the catalytic vapour phase hydrogenation of carboxylic acids or their derivatives using a tin catalyst | AVENTIS RES & TECH GMBH & CO (DE) | 1999-12-01 | — | — | EP | claimed |
| US-5585523-A | APPLYING TIN CATALYST TO OXIDE SUPPORT TO FORM CATALYST, HYDROGENATING ACID IN THE PRESENCE OF CATALYST | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-12-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | KDM4E 3285/4885CA1 879/4885CA2 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.